Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th
A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
